Enjoy complimentary customisation on priority with our Enterprise License!
The NTRK fusion gene positive advanced solid tumor market size is forecast to increase by USD 92.6 million at a CAGR of 4.5% between 2023 and 2028. The market is experiencing significant growth due to the increasing incidence of cancer, particularly those with proteomics and NTRK gene fusions. This subtype of cancer is characterized by the fusion of the neurotrophic tyrosine receptor kinase (NTRK) genes, ophthalmology leading to uncontrolled cell growth and proliferation. The high demand for biomarker-based tests to identify NTRK gene fusions is another key growth factor, as these colorectal cancer tests enable personalized treatment approaches using targeted therapies. However, the scarcity of skilled laboratory technicians and the high cost of these advanced therapies pose challenges to the market's growth. Despite these challenges, the market is expected to expand at a robust pace due to the unmet medical need for effective treatments for NTRK fusion gene positive advanced solid tumors.
The Market is a rapidly evolving sector in the field of cancer treatment. This market is driven by the genetic makeup of certain cancers, including those with Ntrk gene fusions. Lifestyle and medical history play a role in the development of these cancers in cancer patients. Genetic testing is crucial in identifying the presence of Ntrk gene fusions, which can lead to personalized treatment plans. Advanced solid tumors, such as infantile fibrosarcomas and secretory breast carcinoma, can be characterized by specific genetic mutations and chromosomal rearrangements that result in oncogenesis. The diagnostics segment of the market is propelled by the use of biomarkers and advanced sequencing methods, such as Next Generation Sequencing, to identify Ntrk gene fusions. Targeted therapies are becoming increasingly important in cancer treatment, and the Ntrk Fusion Gene Positive Advanced Solid Tumor Market is no exception. Clinical trials are ongoing to explore the efficacy of these therapies in treating rare cancers with Ntrk gene fusions. The market is expected to grow significantly in the coming years as more effective treatments are developed and approved for use. In summary, the Market is an essential area of research and development in the field of cancer treatment. It is driven by the genetic makeup of certain cancers, the use of advanced diagnostics, and the development of targeted therapies for personalized treatment plans. The market is expected to continue growing as more is learned about the role of genetics in cancer and as new treatments are developed.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD million " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The clinical segment is estimated to witness significant growth during the forecast period. Advanced solid tumors, including infantile fibrosarcomas, secretory breast carcinoma, and prostate cancer, among others, are characterized by genetic mutations that drive oncogenesis. The genetic makeup and medical history of cancer patients play a crucial role in determining the underlying drivers of these tumors.
Get a glance at the market share of various regions Download the PDF Sample
The clinical segment was the largest segment and valued at USD 258.30 million in 2018. Genetic testing, facilitated by DNA Next Generation Sequencing (NGS) panels such as FoundationOne, is essential for identifying NTRK fusions and other genomic alterations. Personalized treatment plans are increasingly being adopted based on these genetic findings. Genetic counsellors and hospitals collaborate to ensure accurate diagnosis and effective therapeutic decision making. NTRK fusions, which can occur in various cancers, have emerged as promising biomarkers for targeted therapies, such as larotrectinib. Hence, such factors are fuelling the growth of this segment during the forecast period.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 40% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. Advanced solid tumors, including infantile fibrosarcomas, secretory breast carcinoma, and prostate cancer, in cancer patients are increasingly being characterized by their genetic makeup and medical history. Genetic mutations, specifically NTRK fusions, have emerged as key drivers in the development of personalized treatment plans. Genetic testing, facilitated by DNA Next Generation Sequencing (NGS) panels such as FoundationOne, plays a crucial role in identifying these genetic alterations. Genetic counsellors and hospitals collaborate to ensure accurate diagnosis and effective therapeutic decision making. Biomarkers derived from genomic profiling are essential in the diagnostics segment, with sequencing methods like NGS enabling the identification of these markers. Hence, such factors are driving the market in North America during the forecast period.
Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Increasing incidence of cancer is notably driving market growth. The NTRK fusion gene is linked to a small subset of cancers, including rare types such as melanoma, glioma, and certain carcinomas of the thyroid, lung, and colon. Among all cancers, lung cancer is the most prevalent globally, with the European Commission reporting that it accounted for 54% of new cases and 56% of deaths among men in 2020.
Moreover, in the United States, common cancers include breast cancer, colon and rectum cancer, prostate cancer, and tracheal, bronchus, and lung cancer. The treatment paradigm for NTRK fusion gene-positive advanced solid tumors is rapidly evolving, with continued research and innovation in targeted therapies. Thus, such factors are driving the growth of the market during the forecast period.
High demand for biomarker-based tests is the key trend in the market. The NTRK fusion gene positive advanced solid tumor market is witnessing significant advancements due to continued research and innovation in the rapidly evolving field of molecular biomarkers. Sophisticated R&D in proteomics, nucleic acid expression, and genome sequencing has led to the identification of various biomarkers, including NTRK fusion genes, which are essential in detecting the presence of advanced solid tumors.
Moreover, these biomarkers are expected to replace conventional drug therapeutics with personalized test devices, leading to increased revenue and sales for manufacturers. Thus, such trends will shape the growth of the market during the forecast period.
Dearth of skilled laboratory technicians is the major challenge that affects the growth of the market. The NTRK fusion gene positive advanced solid tumor market is witnessing continued research and innovation, driven by the need to improve treatment paradigms for patients with rare and aggressive forms of cancer. Liquid biopsy systems, such as polymerase chain reaction (PCR) and assays, play a crucial role in the diagnosis and monitoring of these cancers.
However, the shortage of skilled lab technicians capable of handling these complex tests is a significant challenge in the market. This issue is particularly prevalent in hospitals and clinical and diagnostic laboratories in developing and underdeveloped regions of Asia Pacific and the Sub-Saharan area. Hence, the above factors will impede the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Bayer AG: The company offers precision oncology treatment Vitrakvi that is approved for the treatment of NTRK fusion-positive advanced or recurrent solid tumors.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The NTRK fusion gene positive advanced solid tumor market is a rapidly evolving sector in the field of oncology, driven by the genetic makeup and lifestyle factors, medical history, and cancer patients with specific genetic mutations. The identification of NTRK fusions through genetic testing has led to the development of personalized treatment plans for various types of advanced solid tumors, including infantile fibrosarcomas, secretory breast carcinoma, and prostate cancer. The diagnostics segment of this market is propelled by the use of DNA NGS panels, such as Foundation One, for genomic profiling and therapeutic decision making. The market landscape depends on the Genetic makeup, lifestyle, non-small cell lung cancer, drug development, plasma cell-free DNA profiling, diagnostic tools. Drivers for the market include ongoing research efforts at various research institutions and regulatory approvals for targeted therapies like larotrectinib. However, resistance mechanisms and treatment outcomes remain significant challenges in the NTRK fusion gene positive advanced solid tumor market. Biomarkers and sequencing methods, such as Next Generation Sequencing, life science play a crucial role in drug discovery and development. The oncology community emphasizes the importance of clinical trials and genetic studies in understanding the oncogenesis of these rare cancers and improving cancer treatment.
Moreover, understanding the genetic makeup and genetic roots of cancer is crucial for advancing cancer research and treatment. For instance, non-small cell lung cancer (NSCLC) can be influenced by both genetic and lifestyle factors, highlighting the importance of personalized medicine. Fluorescence in situ hybridization (FISH) is a vital tool in identifying genetic abnormalities associated with various cancers, including mixed congenital mesoblastic nephromas. Researchers are continually examining the drivers and restraints of cancer development to better understand its complexity. By integrating insights from genetic roots of cancer with advancements in diagnostic technologies like FISH, scientists aim to develop targeted therapies. This holistic approach enhances the ability to address diverse cancer types, including NSCLC and rare tumors, while also considering the impact of lifestyle on genetic predispositions and overall health.
Market Scope |
|
Report Coverage |
Details |
Page number |
123 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.5% |
Market growth 2024-2028 |
USD 92.6 million |
Market structure |
Concentrated |
YoY growth 2023-2024(%) |
4.23 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 40% |
Key countries |
US, UK, China, Germany, and Japan |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Bayer AG, Empire Genomics Inc., F. Hoffmann La Roche Ltd., LGC Clinical Diagnostics Inc., NeoGenomics Laboratories Inc., and OncoDNA |
Market dynamics |
Parent market analysis, market report , market forecast , Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.